Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Wilcken

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
The Cochrane Database of Systematic Reviews|July 18, 2014
Treating metastatic breast cancer: the evidence for targeted therapyNicholas Wilcken
The Lancet. Oncology|January 11, 2012
Nine lettersNicholas Wilcken
The Lancet. Oncology|June 18, 2002
Mammography screeningNicholas Wilcken
The Lancet. Oncology|December 10, 2003
Periodic funny turnsNicholas Wilcken
Annals of Internal Medicine|November 3, 2025
After endocrine therapy for postmenopausal early breast cancer, allocation to aromatase inhibitors reduced recurrence at 10 yNicholas Wilcken,
Lancet (London, England)|May 22, 2007
Ovarian suppression for early breast cancerNicholas Wilcken, Martin Stockler
European Journal of Cancer (Oxford, England : 1990)|August 30, 2008
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007Nicholas Wilcken, Rachel Dear
Annals of Internal Medicine|September 16, 2015
In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fracturesNicholas Wilcken, Clara Inkyung Lee
Australian Family Physician|February 2, 2008
Beyond chemotherapy--demystifying the new 'targeted' cancer treatmentsRachel Dear, Nicholas Wilcken, Jenny Shannon
Australian Family Physician|May 9, 2006
Metastatic breast cancerAmanda Stevanovic, Philip Lee, Nicholas Wilcken
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
The Cochrane Database of Systematic Reviews|July 18, 2014
Treating metastatic breast cancer: the evidence for targeted therapyNicholas Wilcken
The Lancet. Oncology|January 11, 2012
Nine lettersNicholas Wilcken
The Lancet. Oncology|June 18, 2002
Mammography screeningNicholas Wilcken
The Lancet. Oncology|December 10, 2003
Periodic funny turnsNicholas Wilcken
Annals of Internal Medicine|November 3, 2025
After endocrine therapy for postmenopausal early breast cancer, allocation to aromatase inhibitors reduced recurrence at 10 yNicholas Wilcken,
Lancet (London, England)|May 22, 2007
Ovarian suppression for early breast cancerNicholas Wilcken, Martin Stockler
European Journal of Cancer (Oxford, England : 1990)|August 30, 2008
Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007Nicholas Wilcken, Rachel Dear
Annals of Internal Medicine|September 16, 2015
In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fracturesNicholas Wilcken, Clara Inkyung Lee
Australian Family Physician|February 2, 2008
Beyond chemotherapy--demystifying the new 'targeted' cancer treatmentsRachel Dear, Nicholas Wilcken, Jenny Shannon
Australian Family Physician|May 9, 2006
Metastatic breast cancerAmanda Stevanovic, Philip Lee, Nicholas Wilcken
Pageof 6